Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
- Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
- 15 Pharmacies Wrongly Claimed 41.6 Million Yen in Dispensing Fees Over 6 Year Period: Board of Audit
November 7, 2012
- Kampo Should Be Excluded from Denominator to Figure out Generic Volume Share
November 5, 2012
- CSIMC Expert Subcommittee Supports Continuation of Different NHI Prices for Long-Listed Drugs and Generics
November 2, 2012
- PAFSC’s 2nd Committee Recommends Additional Indication for Biosimilar Gran
November 2, 2012
- Number of Diseases Eligible for Medical Aid Would Increase to Over 300 Under New Proposal
November 1, 2012
- RMP to Be Made Available through the Internet During Review Stage: Director Tawaragi of PFSB
October 30, 2012
- MHLW Earmarks 200 Mil. Yen for Drug Quality Assurance and Development of New Vaccine Quality Test Methods as Part of Emergency Economic Measures
October 30, 2012
- Japan Adopts Emergency Economic Package, 3.8 Billion Yen Front-Loaded for iPS Research, Drug Discovery Support
October 30, 2012
- PAFSC’s 1st Committee Recommends Approval for Pfizer’s OAB Drug Toviaz
October 29, 2012
- DPJ Vice President Sengoku Says JMA “Paranoid” over TPP Concerns
October 29, 2012
- Keidanren, JCCI Call for Expansion of R&D Tax Break System at Tax Commission Hearings
October 29, 2012
- Number of Pharmacies in Japan Rises to 54,780 as of FY2011 End: MHLW
October 29, 2012
- MHLW Unveils Action Plan for 5-Year Clinical Trial Activation Plan
October 26, 2012
- MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
- US Paperwork Reduction Act Will Not Affect ICH PBRER Guidelines: MHLW
October 26, 2012
- BBPD to Seek Reductions in Market Prices of Domestic Blood Products: New BBPD Director Kato
October 26, 2012
- Basic Bill for Regenerative Medicine to Be Submitted to Extraordinary Diet by Bipartisan Lawmaker-Initiated Legislation
October 26, 2012
- METI and MEXT Call for Increase in R&D Tax Credit
October 25, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…